Medivation, Inc. (NASDAQ:MDVN)
A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
campwt00global
(88.26)
Submitted: 2/2/2012 10:29:27 AM :
Start Price:
$69.14
MDVN Score:
+2.97
big pop and move up this year....like 300% 12 months.....think this is due a leg down while the dust settles on the Fda
Recs
sikiliza
(71.92)
Submitted: 2/1/2012 2:32:08 PM :
Start Price:
$41.49
MDVN Score:
-51.96
Got caught on the wrong side of this one because I under-estimated its potential
Recs
baselineace
(57.84)
Submitted: 12/30/2011 3:48:02 PM :
Start Price:
$38.72
MDVN Score:
-68.16
Overextended
Recs
portefeuille
(99.81)
Submitted: 12/23/2011 5:01:19 AM :
Start Price:
$21.61
MDVN Score:
+213.78
There are currently 620 MDVN shares in my "fund" with break-even of around 2.36 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
Olddognwtrx
(< 20)
Submitted: 11/20/2011 10:02:14 AM :
Start Price:
$41.49
MDVN Score:
+51.96
MDV3100 looks as if it might take much of the prostate cancer market and work in breast cancer also. Sales of 2 billion on the low side. Someone will buy them after the launch. 100+ by the end of 2012. Buy on any dips and add slowly.
Recs
MajorBob04
(76.26)
Submitted: 11/3/2011 9:32:54 AM :
Start Price:
$36.81
MDVN Score:
+77.08
This stock will skyrocket now that trial results are positive and indicating that trial participants receiving the placebo will switch to the actual drug because of efficacy.
Recs
PharmaD
(62.43)
Submitted: 10/26/2011 11:11:58 PM :
Start Price:
$17.45
MDVN Score:
+284.04
Phase 3 data coming soon..... And will likely be great
Recs
zzlangerhans
(99.26)
Submitted: 8/25/2011 12:28:39 PM :
Start Price:
$14.91
MDVN Score:
+340.90
Hopefully Dimebon has now provided enough failures to reduce its contribution to Medivation's enterprise value to zero. The new central story is the promising prostate cancer drug MDV3100 . In June the company reported preliminary data from an MD Anderson study of MDV3100 showing that 45% of 55 advanced prostate ca patients experienced at least a 50% decrease in PSA levels. An interim analysis of the AFFIRM phase III placebo controlled trial of MDV3100 in castration-resistant prostate cancer may be performed before the end of the year. The share price hasn't seen 15 since February, when encouraging data for MDV3100 first started to get noticed.
Recs
KurtEng
(51.17)
Submitted: 8/17/2011 4:22:41 PM :
Start Price:
$15.67
MDVN Score:
-318.20
I would never put my own money into this stock. They will have to grow like crazy to justify the current price and so far they haven't generated any positive cash flow. The downside seems huge.
Recs
musclemilk13
(98.58)
Submitted: 4/26/2010 3:24:01 PM :
Start Price:
$11.37
MDVN Score:
+486.88
copying andrelikesMTL
Recs
pjani06
(54.51)
Submitted: 3/25/2010 1:20:41 AM :
Start Price:
$11.77
MDVN Score:
+462.96
stock picks with the potential of being doublers to multibaggers, yet risky, very risky and can go nearly to 0. hated by CAPs, but they have atleast 1 CAPs allstar that I like that has greenthumbed this one. These things have been beaten, and if 2 of 6 of em double, and another 2 don't even move, well it makes up if the last 2 go to zero n basically tank.
DMAN, FSLR, IDRA, ARQL, OSIR, MDVN
Recs
Pollywol
(< 20)
Submitted: 3/6/2010 5:31:31 AM :
Start Price:
$13.09
MDVN Score:
+399.50
The drug may not be completely dead yet, says University of Southern California Alzheimer's expert Lon Schneider.
Recs
ThankHedgens
(82.65)
Submitted: 3/3/2010 11:24:19 AM :
Start Price:
$13.27
MDVN Score:
+392.91
Just like Xenoport last week this is an overreaction to bad news. Is it really bad news? Yes. Will the price return to half it's heights? Probably not. Will it have a decent correction after a 70% sell off? Absolutely.
Recs
coley34
(< 20)
Submitted: 2/10/2010 4:19:58 PM :
Start Price:
$36.18
MDVN Score:
+62.05
Company will be releasing important drug aimed at helping alzheimer patients.
Recs
Recs
becon800
(99.79)
Submitted: 12/18/2009 11:18:28 AM :
Start Price:
$35.50
MDVN Score:
+69.81
Alzheimer's Phase III data expected in 2010 could make this 1b market cap company triple.
Recs
StockSouter
(39.33)
Submitted: 11/3/2009 2:59:08 PM :
Start Price:
$26.63
MDVN Score:
+126.17
Stock is priced on MDV 3100 future revenue alone which gets you the dimebon chance for success for free
Recs
lfjl
(66.98)
Submitted: 9/9/2008 3:31:57 PM :
Start Price:
$33.00
MDVN Score:
-93.92
stock just climbed too high too fast, I don't expect it to stay here. Time to short.
Recs
bigreenmountain
(85.19)
Submitted: 8/6/2008 1:51:08 AM :
Start Price:
$14.98
MDVN Score:
+353.85
effective new alzheimers drug
Recs
lcscarce
(32.91)
Submitted: 7/31/2008 10:38:48 PM :
Start Price:
$20.00
MDVN Score:
+230.41
With the new data out on the positive reports on the new alzheimer's drug and a great management team, I feel this company will out perform the S&P due to the economic downturn. Also with the increase in alzheimer's victums the drug is needed, so this breaktrough is a positive step forward.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 26 : 1 2 Next »